GlassScriptPhysician profile
Ike Onwere
NPI 1467454025
$17,183.45
in general payments reported to CMS, 2019-2025
51 companies · $832 in 2025
The $832 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,961 · 2020: $563 · 2021: $987 · 2022: $3,938 · 2023: $658 · 2024: $246 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.00 |
| Education | $357.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $7,555.74 | 2019-2025 | Reblozyl |
| Genentech USA, INC. | $2,337.27 | 2019-2025 | Polivy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,469.34 | 2019 | |
| Janssen Scientific Affairs, LLC | $1,024.39 | 2019-2022 | |
| Janssen Biotech, INC. | $481.15 | 2019-2024 | Rybrevant |
| Amgen INC. | $363.04 | 2019-2022 | |
| Lilly USA, LLC | $336.82 | 2019-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $287.72 | 2019-2025 | Ninlaro, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $244.39 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $213.32 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $203.98 | 2019-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $189.95 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Pfizer INC. | $171.39 | 2019-2025 | |
| Genzyme Corporation | $165.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $157.73 | 2019-2023 | Keytruda, Lynparza |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ike Onwere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.